Carfilzomib
Kyprolis (carfilzomib) is a protein pharmaceutical. Carfilzomib was first approved as Kyprolis on 2012-07-20. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. The pharmaceutical is active against proteasome subunit beta type-5. Kyprolis's patents are valid until 2033-02-27 (FDA).
| Trade Name | Kyprolis |
|---|---|
| Common Name | Carfilzomib |
| ChEMBL ID | CHEMBL451887 |
| Indication | multiple myeloma |
| Drug Class | Proteozome inhibitors |
